Abstract
Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.
Original language | English (US) |
---|---|
Pages (from-to) | 113-118 |
Number of pages | 6 |
Journal | Annals of the New York Academy of Sciences |
Volume | 1003 |
DOIs | |
State | Published - Nov 2003 |
Keywords
- Glutamatergic system
- Ketamine
- MK-801
- Molecular targets
- PCP
- Psychosis
- Schizophrenia
ASJC Scopus subject areas
- General Neuroscience
- General Biochemistry, Genetics and Molecular Biology
- History and Philosophy of Science